Authors
Zdeněk Dvořák, Felix Kopp, Cait M Costello, Jazmin S Kemp, Hao Li, Aneta Vrzalová, Martina Štěpánková, Iveta Bartoňková, Eva Jiskrová, Karolína Poulíková, Barbora Vyhlídalová, Lars U Nordstroem, Chamini V Karunaratne, Harmit S Ranhotra, Kyu Shik Mun, Anjaparavanda P Naren, Iain A Murray, Gary H Perdew, Julius Brtko, Lucia Toporova, Arne Schön, Bret D Wallace, William G Walton, Matthew R Redinbo, Katherine Sun, Amanda Beck, Sandhya Kortagere, Michelle C Neary, Aneesh Chandran, Saraswathi Vishveshwara, Maria M Cavalluzzi, Giovanni Lentini, Julia Yue Cui, Haiwei Gu, John C March, Shirshendu Chatterjee, Adam Matson, Dennis Wright, Kyle L Flannigan, Simon A Hirota, Ryan Balfour Sartor, Sridhar Mani
Publication date
2020/4/7
Journal
EMBO molecular medicine
Volume
12
Issue
4
Pages
e11621
Description
The human PXR (pregnane X receptor), a master regulator of drug metabolism, has essential roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off‐target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows exploiting previously unexplored parts of chemical space. Here, we report functionalized indole derivatives as first‐in‐class non‐cytotoxic PXR agonists as a proof of concept for microbial metabolite mimicry. The lead compound, FKK6 (Felix Kopp Kortagere 6), binds directly to PXR protein in solution, induces PXR‐specific target gene expression in cells, human organoids, and mice. FKK6 significantly represses pro‐inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The …
Scholar articles
Z Dvořák, F Kopp, CM Costello, JS Kemp, H Li… - EMBO molecular medicine, 2020